Background: Hodgkin lymphoma (HL) survivors have an increased risk of secondary malignancies. We analyzed outcomes in patients with lung cancers following HL treatment.
introduction
Advancements in Hodgkin lymphoma (HL) treatment over the past half century have greatly improved disease outcomes. Current approaches cure the majority of all patients and generally >90% of those with early-stage disease [1] . Consequently, increased attention has focused on long-term morbidities of HL treatment. With increasing time after initial treatment, mortality from second malignancies eventually surpasses that of HL [2] [3] [4] . Thoracic malignancies, in particular, account for a significant percentage of late deaths in HL patients [4, 5] .
Previous work has delineated risk factors for developing a thoracic malignancy following HL treatment. Treatmentrelated risk factors include radiotherapy to the thorax [6] [7] [8] and while there are conflicting earlier data in regards to the risk posed by chemotherapy [8] [9] [10] [11] , more recent data showed a significant contribution of alkylating chemotherapy to lung cancer risk in a dose-related manner [6, [12] [13] [14] . Patient tobacco use increases risk in a multiplicative fashion [6, 8] . In contrast, data regarding outcomes of thoracic malignancies that develop following HL treatment are sparse. These cancers tend to be diagnosed at advanced stages and have poor outcomes [15] [16] [17] . Treatment options can be limited by previous HL therapy [16, 17] .
We previously reported our experience with 33 thoracic malignancies detected after HL therapy in patients included in a multi-institutional database [16] . We now update this experience and report on 55 patients with thoracic tumors, focusing on the disease characteristics, detection methods and clinical outcomes.
patients and methods
With the institutional review board approval and a waiver of consent, records were retrospectively obtained from a multi-institutional database of 1976 patients treated for HL from 1969 to 2007 at the following Harvard-affiliated hospitals in Boston, MA: Brigham and Women's Hospital, Dana-Farber Cancer Institute, Children's Hospital and Beth Israel Deaconess Medical Center. Histological classification for all patients was confirmed by hematopathologists at the treating hospital. All patients had undergone clinical staging with history and physical examination, chest radiography, complete blood counts and chemistries.
Information regarding demographics, risk factors, disease characteristics and outcomes was obtained by review of all available medical records. Overall survival was calculated according to the method of Kaplan and Meier [18] from the date of lung cancer diagnosis. Frequency distribution comparisons between subgroups were carried out using Pearson's chi-square test. SAS software (Cary, NC) was used for all analyses.
results

patient characteristics
Fifty-five patients with thoracic malignancies diagnosed after HL treatment were retrospectively identified; these constitute the study population. Characteristics of the entire cohort of 1976 patients and the 55 patients who developed thoracic malignancies following HL treatment are summarized in Table 1 . In patients who developed lung malignancies, the median age at HL diagnosis was 30 years (interquartile range, 24-30 years). The most common HL histology was nodular sclerosing (n = 34). The majority of patients had early-stage HL at diagnosis.
Initial HL treatment in patients who developed lung malignancies was delivered from 1970 to 1999 and included radiation therapy in 47 patients (85%). Extended field treatment was typically given during this period. The thorax was included in the radiation treatment field in all but two patients (96%). Twenty patients (36%) received chemotherapy, of whom 14 (70%) were treated with MOPP-based chemotherapy. Fifteen patients had eventual relapse of their HL and received salvage chemotherapy (n = 10), combined modality therapy (n = 4) or radiation therapy alone (n = 1). One patient with a second recurrence after combined modality salvage treatment also received additional chemotherapy and a hematopoietic stem cell transplant. Eleven patients who developed lung malignancies also were diagnosed with another malignancy after HL treatment, eight of which occurred before their lung malignancy.
risk factors for the development of lung malignancy
Tobacco history was known for 46 of 55 patients (84%) ( Table 2 ). Nine patients (16%) had no history of tobacco use, six (11%) had a <10 pack-year history and 31 (56%) had a ≥10 pack-year history. No patient had known asbestos exposure. Forty-eight patients (87%) had received radiation to the thorax as treatment of HL. The median dose delivered to the mantle field in irradiated patients was 37.80 Gy (range, 30.60-43.20 Gy). Whole-lung irradiation was given to four patients (7%) and ranged from 13.50 to 20 Gy. Twenty-six patients (47%) received alkylating chemotherapy at some point during their treatment course.
All patients who developed lung malignancies after HL had at least one of the following risk factors: a ≥10 pack-year tobacco history, prior thoracic irradiation or exposure to alkylating chemotherapy. Thirty-one patients (56%) had two factors and 10 patients (18%) had all three risk factors.
lung malignancies
Subsequent lung malignancies were diagnosed at a median age of 52 years (range, 30-88 years), a median of 19.5 years (range, 1-41 years) after completion of initial HL treatment ( Table 3) . The most common histology was non-small-cell lung cancer (NSCLC) in 38 patients (69%). Histological subtype of NSCLC was available for 24 patients and included adenocarcinoma (n = 17), squamous cell carcinoma (n = 6) and bronchoalveolar carcinoma (n = 1). Other histologies included small-cell lung The circumstances surrounding initial lung cancer detection were known for 35 patients (64%). In 12 patients (34%), the diagnosis was made incidentally: five on a computed tomography (CT) of the chest, four on a chest radiograph and one patient each on breast magnetic resonance imaging (MRI), CT of the neck and positron emission tomography scan. The rationale for the scans on which lung lesions were incidentally noted included HL follow-up, breast cancer screening, breast cancer follow-up, lung cancer screening, preoperative chest radiograph (CXR) screening, neck pain, nephrolithiasis, chronic obstructive pulmonary disease follow-up and CXR carried out during evaluation of cellulitis. Nine patients (75%) with incidentally diagnosed tumors had a >10 pack-year tobacco history. In the remaining 23 patients, the lung cancer was detected on studies obtained as a result of signs and symptoms related to the lung cancer diagnosis, and these included pulmonary symptoms, bony pain, central nervous system symptoms, abdominal pain, weight loss, facial swelling or a palpable mass. Nine of the lung cancers were diagnosed on a CT of the chest, seven on chest radiograph, two on thoracentesis and one each on brain CT, brain MRI, CT of the abdomen/pelvis, bone scan and biopsy of a palpable lymph node. Patients with incidentally detected tumors were more likely to have a favorable ECOG PS (P = 0.006) and an earlier stage of lung cancer at diagnosis (P = 0.02) ( Table 4) . Sixteen patients were treated definitively with surgery with or without chemotherapy and/or radiation, 1 was treated definitively with radiation, 25 were treated palliatively and for 13 patients, the type of initial lung cancer treatment was unknown.
lung cancer outcomes
The median survival time after the diagnosis of lung cancer was 10.3 months (mean, 18 months) (Figure 1 ). Patients whose lung tumors were detected incidentally had a significantly longer survival time than those who were symptomatic (Figure 2) . With a median follow-up time of 39 months, the median survival time for patients with incidentally detected lung cancer has not been reached, whereas the median survival time for patients with symptomatic disease at diagnosis was 9.1 months (P < 0.001). Eight of the 12 patients who were diagnosed incidentally were alive at last follow-up (6 with no evidence of disease) at a median of 48 months. Only 2 of the Median survival times were 16.6 versus 4.4 months for patients diagnosed with PS of zero to one versus PS of two to three (P = 0.006). Median survival has not been reached for patients diagnosed with stage I/II disease, in comparison to a median 9.5 months survival for patients diagnosed with stage III/IV disease (P < 0.001). The 8 patients diagnosed with an additional second malignancy before their diagnosis of lung cancer had a median survival of 13.7 months, not significantly different from the other 47 patients (P = 0.73). Four patients have no evidence of disease >36 months after their initial lung cancer diagnoses. One was diagnosed at age 54, 23 years after mantle and paraaortic radiation (MPA) for stage IIA nodular sclerosing (NS) HL, when a lung lesion was identified on a chest radiograph carried out during the evaluation of nephrolithiasis. The second patient was diagnosed on routine follow-up CT scan at age 30, 19 years after MPA radiation for stage IIA NS HL and 8 years after an HL recurrence treated with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy. The third patient was diagnosed at age 48, 8 years after mantle radiation for stage 1A NS HL, by means of a chest CT carried out for the purpose of lung cancer screening. The final patient was diagnosed at age 39, 24 years after MPA radiation for stage IIA NS HL, by means of a CT of the neck carried out for unrelated neck pain. The four patients currently remain without evidence of disease 4, 3.5, 4 and 9 years after their lung-cancer diagnoses, respectively. All four had stage 1 NSCLC (three adenocarcinomas and one squamous cell carcinoma) at diagnosis and were treated definitively with surgery alone. Two had significant (≥10 pack-year) histories of tobacco use.
discussion
This study describes our updated multi-institutional experience with subsequent thoracic malignancies in long-term HL survivors. Fifty-five patients developed lung malignancies up to 41 years after HL therapy. This is consistent with other reported series that describe a long-term increased risk of thoracic malignancies extending for decades following HL treatment [6, 19, 20] . In the current study, patients who developed lung malignancies after HL frequently had multiple risk factors, including previous exposure to thoracic radiation (typically extended field) and a significant history of tobacco use.
The majority of patients were diagnosed with lung cancer at an advanced stage, with 67% of patients having either stage III or stage IV disease. Overall, patients with lung malignancies after HL did quite poorly, with a median survival time of 10.3 months and few long-term survivors. Though eight patients developed a second malignancy before the development of lung cancer and received additional treatments that could have potentially influenced their lung cancer outcomes, survival for this group was not significantly different from the overall cohort. However, we did note a significantly longer survival time in the 12 patients with incidentally diagnosed cancers, 8 of whom had stage I or II disease (median survival time not reached with a median follow-up of 39 months). Seven patients with early-stage disease and one with advanced-stage disease at diagnosis remain alive at last follow-up (median 48 months after initial diagnosis), six with no evidence of disease.
Although various series have explored the risk factors for and frequency of lung malignancies after HL treatment, data regarding the outcomes of these malignancies are limited, and no studies have evaluated method of diagnosis as a predictor of outcome. The overall poor outcomes reported in the current trial are consistent with both our earlier experience [16] and others reported in the literature [15, 17] . Laurie et al. [17] [19] . To our knowledge, this study is the first to identify a subgroup of HL patients with subsequent incidentally diagnosed lung malignancies who have a significantly longer survival time than that seen in patients who present with symptomatic disease. Our results suggest that cure is indeed possible, and even likely, in patients with incidentally diagnosed lung cancer after HL treatment.
The increased survival that we observed in patients with incidentally diagnosed lung cancers affirms the potential utility of lung cancer screening in HL survivors. Screening for breast cancers in young women treated for HL has been recommended to start ∼8 to 10 years after HL treatment [20] . Lung cancer screening with low-dose CT previously demonstrated promise in certain high-risk populations [21] [22] [23] and was recently reported to provide a 20% lung cancer mortality benefit in smokers and former smokers aged 55-74 in the National Lung Screening Trial (NLST) [24] . Cancers detected by CT screening were more likely to be early stage and less likely to be metastatic, as were the incidentally detected lung cancers in our study. Whether CT-based lung cancer screening may also benefit a subgroup of HL survivors, and particularly those with multiple risk factors [25] , remains to be seen.
Our study is limited by its retrospective nature and the incomplete data regarding lung cancer diagnosis and outcome in a minority of patients. Although patients who received thoracic radiotherapy were treated to comprehensive mantle fields and with whole-lung radiation in some cases, we cannot definitively conclude that their lung malignancies developed within the irradiated field. However, by further confirming the poor prognosis in most patients diagnosed with lung cancer after HL treatment, our study highlights the continued need to prevent and reduce the late effects of treatment. Previous studies have shown a significant radiation dose-response relationship in regard to lung cancer development after HL therapy [6] . Hodgson et al. [26] using a radiobiological model, showed that the transition from 35 Gy of mantle irradiation to 35 Gy or to 20 Gy of involved-field irradiation predicted for a 21% and 57% reduction, respectively, in the median excess relative risk of lung cancer. For patients treated in the modern era with combined modality therapy, ABVD-based chemotherapy rather than alkylating chemotherapy is used. In addition, recent efforts have focused on reducing the intensity of HL treatment as part of combined modality therapy, such as by decreasing the amount of chemotherapy [27, 28] , the radiation dose [27] or the radiation fields [27] [28] [29] [30] in selected patients while still preserving excellent outcomes. These efforts, along with smoking cessation counseling, will likely decrease the risk of lung cancers in future HL survivors [26, 31] . 
